



Cyclerion to Present at the J.P. Morgan Healthcare Conference

December 23, 2019

– Management to review the Company's sGC clinical pipeline programs: praligiquat for diabetic nephropathy, olinciquat for sickle cell disease, and IW-6463 for neurodegenerative diseases –

CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it will present at the J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 9AM PST (12PM EST) at the Westin St. Francis in San Francisco in the Elizabethan A Room. The company will also present ongoing and future clinical development plans.

A live webcast of the presentation can be accessed at: <https://jpmorgan.metameetings.net/events/hc20/sessions/29869-cyclerion/webcast>. An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Cyclerion Therapeutics

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion is advancing its portfolio of differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs include praligiquat which recently completed Phase 2 studies and which the company intends to out-license for further development in diabetic nephropathy, olinciquat in Phase 2 development for sickle cell disease, IW-6463 in Phase 1 development for serious and orphan CNS diseases, and two preclinical programs targeting serious liver and lung diseases, respectively.

For more information about Cyclerion, please visit <https://www.cyclerion.com/> and follow us on Twitter ([@Cyclerion](https://twitter.com/Cyclerion)) and LinkedIn (www.linkedin.com/company/cyclerion).

Contact

Carlo Tanzi, Ph.D.
Kendall Investor Relations
617-914-0008
ctanzi@kendallir.com



Source: Cyclerion Therapeutics, Inc.